DURHAM, N.C.--(BUSINESS WIRE)--Jun. 6, 2018--
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced that Richard
Rubino, Chief Financial Officer, will present at the NASDAQ 38th
Investor Conference on Tuesday, June 12, 2018 at 9:00am British Summer
Time in London, UK. Mr. Rubino will provide an Aerie overview and
The presentation will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma and other diseases of the
eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic
solution) 0.02%, for the reduction of elevated intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension, was
approved by the U.S. Food and Drug Administration (FDA) in December
2017 and was launched in the U.S. market in April 2018. A link to the
full product label is available on the Aerie website at http://investors.aeriepharma.com.
Aerie’s advanced-stage product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,
which is a fixed dose combination of Rhopressa® and
widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its
primary efficacy endpoint in two Phase 3 registration trials, named
Mercury 1 and Mercury 2, and also achieved successful 12-month safety
and efficacy results in Mercury 1. The Roclatan™ NDA submission took
place in May 2018. Aerie is also focused on global expansion and the
development of additional product candidates and technologies in
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606005023/en/
Source: Aerie Pharmaceuticals, Inc.
Tad Heitmann, 949-526-8747
McClellan, Inc., on behalf of Aerie Pharmaceuticals